Media-OutReach Newswire Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
Media-OutReach Newswire Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China